(Reuters) - The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17, to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy. The FDA has called for a joint meeting of the bone, reproductive and urologic drugs advisory committee and the drug safety and risk management advisory committee. These treatments are used by men who have low levels of testosterone.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment